Efficacy and safety of ecabet sodium on functional dyspepsia: A prospective, double-blinded, randomized, multi-center controlled trial

doi:10.3748/wjg.v12.i17.2756

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 17

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2775)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

301

HTML

2234

Figures (1-1)

124

Tables (1-7)

116

Sum=2775

May 7, 2006 (publication date) through May 5, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. May 7, 2006; 12(17): 2756-2761
Published online May 7, 2006. doi: 10.3748/wjg.v12.i17.2756

Table 1 Demographic characteristics of the enrolled patients

Group	Ecabet group	Cimetidine group	P
Group	(n = 133)	(n = 139)	P
Gender (male:female)	47:86	47:92	NS
Age (yr)	45.0 ± 12.9	47.5 ± 12.5	NS
Weight (kg)	59.6 ± 10.0	58.5 ± 9.0	NS
Height (cm)	162.7 ± 8.0	161.8 ± 7.7	NS
Smoking (%)	23 (17.3)	16 (11.5)	NS
Alcohol intake (%)	47 (35.3)	38 (27.3)	NS

Table 2 Prevalence of Helicobacter pylori infection

Group	Positive (%)	Negative (%)	Undetermined (%)
Ecabet group	44	45	31
(n = 120)	(36.7)	(37.5)	(25.9)
Cimetidine group	40	60	28
(n = 128)	(31.3)	(46.9)	(21.9)

Pearson's chi-square test; P = NS.

Table 3 Global assessment of symptomatic improvement after 4 wk of medication

Group	Ecabet group	Cimetidine group
Group	(n = 115) (%)	(n = 121) (%)
Improved	89 (77.4)	96 (79.3)
Not improved	26 (22.6)	25 (20.7)

Pearson's chi-square test: P = 0.71.

Table 4 Comparison of quality of life scores before and after treatment (mean±SD)

Status	Before treatment			After treatment
Status	Ecabet group(n = 115)	Cimetidine group(n = 121)	P	Ecabet group(n = 115)	Cimetidine group(n = 121)	P
Eating status	15.0 ± 4.6	14.8 ± 4.1	NS	15.6 ± 4.0	15.9 ± 3.5	NS
Liveliness status	10.4 ± 4.1	10.0 ± 4.0	NS	11.6 ± 3.6	11.3 ± 3.5	NS
Psychological status	18.5 ± 5.0	18.6 ± 4.5	NS	20.3 ± 4.4	20.4 ± 4.1	NS
Role-functioning status	20.5 ± 4.2	20.6 ± 4.2	NS	21.4 ± 3.9	21.0 ± 4.3	NS

Table 5 Comparison of global symptomatic improvement by H pylori status

H pylori infection	Gastrex group		Cimetidine group
H pylori infection	Improved (%)	Not improved(%)	Improved (%)	Not improved (%)
Negative	28 (84.85)	5 (15.15)	27 (84.38)	5 (15.63)
Positive	28 (75.68)	9 (24.32)	24 (72.73)	9 (27.27)

Chi square test, P = 0.89.

Table 6 Comparison of global symptomatic improvement by age

Age	Gastrex group		Cimetidine group
Age	Improveed (%)	Not improved (%)	Improved (%)	Not improved (%)
Less than fifty	55 (61.8)	14 (53.85)	61 (63.54)	12 (48.0)
fifty and over	34 (38.2)	12 (46.15)	35 (36.46)	13 (52.0)

Chi square test, P = 0.63.

Table 7 Comparison of global symptomatic improvement by sex

Sex	Gastrex group		Cimetidine group
Sex	Improved (%)	Not improved (%)	Improved (%)	Not improved (%)
Men	27 (71.05)	11 (28.94)	34 (79.07)	9 (20.93)
Women	63 (80.76)	15 (19.23)	62 (79.48)	16 (20.51)

Chi square test, P = 0.79.

Citation: Lee JH, Kim JJ, Hahm KB, Lee DH, Kim N, Kim SK, Park JJ, Choi SR, Lee JH, Lee ST, Lee EH, Rhee JC. Efficacy and safety of ecabet sodium on functional dyspepsia: A prospective, double-blinded, randomized, multi-center controlled trial. World J Gastroenterol 2006; 12(17): 2756-2761
URL: https://www.wjgnet.com/1007-9327/full/v12/i17/2756.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i17.2756